


**Product Name** : KD025  
**Cat. No.** : PC-73191  
**CAS No.** : 911417-87-3  
**Molecular Formula** : C<sub>26</sub>H<sub>24</sub>N<sub>6</sub>O<sub>2</sub>  
**Molecular Weight** : 452.518  
**Target** : ROCK  
**Solubility** : 10 mM in DMSO



## Biological Activity

KD025 (Belumosudil, SLx-2119) is a potent, selective **ROCK2** inhibitor with IC<sub>50</sub> of 105 nM.

KD025 displays >200-fold selectivity over ROCK1 (IC<sub>50</sub>>20 μM).

KD025 dose-dependently reduced infarct volume after transient middle cerebral artery occlusion, cortical perfusion in a distal middle cerebral artery occlusion model.

KD025 significantly diminished STAT3 phosphorylation and binding to IL-17 and IL-21 promoters and reduced IRF4 and nuclear hormone RAR-γt protein levels in T cells derived from healthy subjects or rheumatoid arthritis patients.

KD025 in vivo down-regulates the progression of collagen-induced arthritis in mice via targeting of the Th17-mediated pathway.

KD025 inhibits the secretion of IL-21, IL-17, and INF-γ along with decreasing p-STAT3 and reduced protein expression of IRF4 and BCL6 in human PBMCs purified from active cGVHD patients.

## References

Flynn R, et al. *Blood*. 2016 Apr 28;127(17):2144-54.

Zanin-Zhorov A, et al. *Proc Natl Acad Sci U S A*. 2014 Nov 25;111(47):16814-9.

Lee JH, et al. *Ann Clin Transl Neurol*. 2014 Jan 1;1(1):2-14.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com